Theseus Pharmaceuticals (THRX) Analyst Estimates Annual - Discounting Cash Flows
Theseus Pharmaceuticals, Inc.
THRX (NASDAQ)

* (except for per share items) of USD
Period Ending: 2025
12-31
2024
12-31
2023
12-31
2022
12-31
Number of Analysts 0 0 0 0
Estimated Revenue
Low 0.00 0.00 0.00 0.00
Average 0.00 0.00 0.00 0.00
High 0.00 0.00 0.00 0.00
Estimated EBITDA
Low
Average
High
Estimated EBIT
Low
Average
High
Estimated Net Income
Low -94.7 -72.4 -58.9 -63.9
Average -88.6 -70.5 -61.4 -50.8
High -23.9 -41.2 -50.8 -37.2
Estimated SGA Expenses
Low
Average
High
Estimated EPS
Low -2.460 -1.880 -1.530 -1.660
Average -1.502 -1.508 -1.430 -1.320
High -0.620 -1.070 -1.320 -0.966
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us